Krystal Biotech Inc

KRYS05 Dec 2024
Healthcare
$186.27
+0.01 (+0.89%)
Lowest Today
$186.27
Highest Today
$190.53
Today’s Open
$186.27
Prev. Close
$185.97
52 Week High
$219.34
52 Week Low
$101.34
To Invest in Krystal Biotech Inc

Krystal Biotech Inc

Healthcare
KRYS05 Dec 2024
+0.01 (+0.89%)
1M
3M
6M
1Y
5Y
Low
$186.27
Day’s Range
High
$190.53
186.27
52 Week Low
$101.34
52-Week Range
52 Week High
$219.34
101.34
1 Day
-
1 Week
-5%
1 month return
+7.46%
3 month return
+0.77%
6 month return
+11.77%
1 Year return
+80.4%
3 Years return
+177.86%
5 Years return
+214.27%
10 Years return
-
Institutional Holdings
FMR Inc
14.93
BlackRock Inc
13.73
Vanguard Group Inc
9.91
venBio Select Advisor LLC
9.12
Fidelity Select Biotechnology
6.53
iShares Core S&P Small-Cap ETF
5.69
State Street Corp
5.05

Market Status

Fundamentals
Market Cap
5605.71 mln
PB Ratio
6.04
PE Ratio
103.89
Enterprise Value
5024.87 mln
Total Assets
818.36 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Organisation
Krystal Biotech Inc
Employees
229
Industry
Biotechnology
CEO
Mr. Krish S. Krishnan M.B.A., M.S.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities